Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography

被引:58
作者
Palumbo, Chiara Saroli [1 ]
Restellini, Sophie [1 ,2 ,3 ]
Chao, Che-Yung [4 ]
Aruljothy, Achuthan [5 ]
Lemieux, Carolyne [1 ]
Wild, Gary [1 ]
Afif, Waqqas [1 ]
Lakatos, Peter L. [1 ,6 ]
Bitton, Alain [1 ]
Cocciolillo, Sila [1 ]
Ghali, Peter [1 ]
Bessissow, Talat [1 ]
Sebastiani, Giada [1 ]
机构
[1] McGill Univ, Div Gastroenterol & Hepatol, Ctr Hlth, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada
[2] Genevas Univ Hosp, Div Gastroenterol & Hepatol, Geneva, Switzerland
[3] Univ Geneva, Geneva, Switzerland
[4] Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld, Australia
[5] McGill Univ, Ctr Hlth, Div Internal Med, Montreal, PQ, Canada
[6] Semmelweis Univ, Dept Med 1, Budapest, Hungary
关键词
Body mass index; controlled attenuation parameter; extrahepatic diseases; STIFFNESS MEASUREMENT; FIBROSIS; CIRRHOSIS; MANIFESTATIONS; DIAGNOSIS; PREDICT; NAFLD;
D O I
10.1093/ibd/izy200
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Inflammatory bowel disease (IBD) patients may be at risk for nonalcoholic fatty liver disease (NAFLD) due to chronic inflammation, hepatotoxic drugs, and alteration of the gut microbiota. Prospective data using accurate diagnostic methods are lacking. Methods We prospectively investigated prevalence and predictors of NAFLD and liver fibrosis by transient elastography (TE) with associated controlled attenuation parameter (CAP) in IBD patients as part of a routine screening program. NAFLD was defined as CAP 248 dB/m. Significant liver fibrosis (stage 2 or higher out of 4) was defined as TE measurement 7.0 kPa. Predictors of NAFLD and significant liver fibrosis were determined by logistic regression analysis. Results A total of 384 patients (mean age 42.4 years, 45.0% male, 64.6% with Crohn's disease) with no significant alcohol intake were included. Prevalence of NAFLD and significant liver fibrosis was 32.8% and 12.2%, respectively. Independent predictors of NAFLD were older age (adjusted odds ratio [aOR], 1.45; 95% confidence interval [CI], 1.15-1.82), higher body mass index (BMI; aOR, 1.31; 95% CI, 1.20-1.42) and higher triglycerides (aOR, 1.45; 95% CI, 1.01-2.09). Significant liver fibrosis was independently predicted by older age (aOR, 1.38; 95% CI, 1.12-1.64) and higher BMI (aOR, 1.14; 95% CI, 1.07-1.23). Extrahepatic diseases were more common in IBD patients with NAFLD compared with those without, namely chronic kidney disease (10.3 vs 2.3%; P < 0.001) and cardiovascular diseases (11.3 vs 4.7%; P = 0.02). Conclusions NAFLD diagnosed by TE with CAP is a frequent comorbidity in IBD patients and is associated with extrahepatic diseases. Noninvasive screening strategies could help early diagnosis and initiation of interventions, including weight loss, correction of dyslipidemia, and linkage to care. fig fig-type=video id=video1 orientation=portrait position="float object-id pub-id-type="doi 10.1093/ibd/izy200_video1 object-id media content-type="brightcove" orientation="portrait" position="float" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href=brightcove
引用
收藏
页码:124 / 133
页数:10
相关论文
共 37 条
[1]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[2]  
[Anonymous], 2015, J HEPATOL, V63, P237, DOI 10.1016/j.jhep.2015.04.006
[3]   Global Guideline for Type 2 Diabetes [J].
不详 .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 104 (01) :1-52
[4]  
[Anonymous], 2011, OB CAN JOINT REP PUB
[5]   Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease [J].
Bessissow, Talat ;
Ngoc Han Le ;
Rollet, Kathleen ;
Afif, Waqqas ;
Bitton, Alain ;
Sebastiani, Giada .
INFLAMMATORY BOWEL DISEASES, 2016, 22 (08) :1937-1944
[6]   Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease [J].
Boursier, Jerome ;
Vergniol, Julien ;
Guillet, Anne ;
Hiriart, Jean-Baptiste ;
Lannes, Adrien ;
Le Bail, Brigitte ;
Michalak, Sophie ;
Chermak, Faiza ;
Bertrais, Sandrine ;
Foucher, Juliette ;
Oberti, Frederic ;
Charbonnier, Maude ;
Fouchard-Hubert, Isabelle ;
Rousselet, Marie-Christine ;
Cales, Paul ;
de Ledinghen, Victor .
JOURNAL OF HEPATOLOGY, 2016, 65 (03) :570-578
[7]   AUDIT-C as a brief screen for alcohol misuse in primary care [J].
Bradley, Katharine A. ;
DeBenedetti, Anna F. ;
Volk, Robert J. ;
Williams, Emily C. ;
Frank, Danielle ;
Kivlahan, Daniel R. .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (07) :1208-1217
[8]   Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients [J].
Carr, Rotonya M. ;
Patel, Arpan ;
Bownik, Hillary ;
Oranu, Amanke ;
Kerner, Caroline ;
Praestgaard, Amy ;
Forde, Kimberly A. ;
Reddy, K. Rajender ;
Lichtenstein, Gary R. .
DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (05) :1354-1361
[9]   Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis [J].
Caussy, Cyrielle ;
Alquiraish, Mosab H. ;
Nguyen, Phirum ;
Hernandez, Carolyn ;
Cepin, Sandra ;
Fortney, Lynda E. ;
Ajmera, Veeral ;
Bettencourt, Ricki ;
Collier, Summer ;
Hooker, Jonathan ;
Sy, Ethan ;
Rizo, Emily ;
Richards, Lisa ;
Sirlin, Claude B. ;
Loomba, Rohit .
HEPATOLOGY, 2018, 67 (04) :1348-1359
[10]  
Chalasani NP, 2017, HEPATOLOGY, V66, p303A